
StocksDaily · 2026-10-27 11:30 UTC
$ARTV Artiva Biotherapeutics — Discontinued AlloNK development, planned Phase 3 will not start — Two Grade 5 events, one likely fludarabine toxicity, FDA had asked to pause enrollment and dosing — Cutting about 94% of staff, exploring strategic alternatives including sale, merger or liquidation — Cash of about $319.1M as of Sept 30, preliminary and unaudited Not financial advice.
Loading the story on Tree News…